Postinflammatory hyperpigmentation - Postinflammatoresch Hyperpigmentatioun
Postinflammatoresch Hyperpigmentatioun (Postinflammatory hyperpigmentation) ass e kutanen Zoustand charakteriséiert duerch erhéicht Pigment an der Haut no der Entzündung vun der Haut. postinflammatoresch hyperpigmentatioun (postinflammatory hyperpigmentation) kann duerch länger Sonnebelaaschtung, Entzündung oder aner Hautverletzungen verursaacht ginn, och déi mat Akne. Leit mat méi däischter Hauttéin sinn normalerweis méi ufälleg fir Hyperpigmentéierung mat iwwerschësseg Sonneliicht.
☆ An den 2022 Stiftung Warentest Resultater aus Däitschland war d'Zefriddenheet vum Konsument mam ModelDerm nëmme liicht manner wéi mat bezuelte Telemedizin Konsultatiounen.
References
Postinflammatory hyperpigmentation (PIH) ass en dacks Hautproblem deen no Hautentzündung oder Verletzung geschitt. Et tendéiert eng laang Zäit ze daueren an ass méi schlëmm bei Leit mat méi däischter Hauttéin (Fitzpatrick skin types III–VI) . Och wann et dacks eleng besser gëtt, kann dat eng Zäit daueren, sou datt d'Behandlung oft laang gebraucht gëtt. D'Kombinatioun vu verschiddene Behandlungen funktionnéiert am beschten.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation ass eng allgemeng Konsequenz vun der Hautentzündung. Et tendéiert méi däischter Haut Individuen méi schwéier an dacks ze beaflossen. Studien weisen datt Themen wéi postinflammatory hyperpigmentation zu den Haaptgrënn sinn firwat Leit mat méi däischter Hauttéin dermatologescher Betreiung sichen. Fréi Behandlung ass entscheedend fir postinflammatory hyperpigmentation ze léisen a fänkt normalerweis mat der Gestioun vum initialen inflammatoreschen Zoustand un. Déi éischt Zeil vun der Behandlung beinhalt typesch d'Benotzung vun topeschen Agenten, déi d'Haut zesumme mat Sonneschutz fir Schutz erliichteren. Dës Agenten, wéi hydroquinone, azelaic acid, kojic acid, arbutin, licorice extracts , kënnen effektiv exzessiv Pigmentéierung reduzéieren. Zousätzlech retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, soy ginn och als Depigmentéierungsmëttel benotzt, mat neie Behandlungen entstanen. Wärend topesch Behandlungen normalerweis effektiv fir Hyperpigmentatioun op Uewerflächenniveau sinn, kënnen Prozeduren (laser, chemical peel) fir haartnäckege Fäll néideg sinn. Et ass wichteg virsiichteg mat dësen Behandlungen ze benotzen fir Reizung a Verschlechterung vun postinflammatory hyperpigmentation ze vermeiden.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
